Bronchiectasis News and Research

RSS
Bronchiectasis is a condition in which the lung’s airways (bronchi) are dilated, causing an accumulation of mucus. This, in turn, makes the patient more vulnerable to infection, which can cause permanent damage. Most affected patients are middle-aged.
Aradigm reports total revenue of $4.0M for first-quarter 2010

Aradigm reports total revenue of $4.0M for first-quarter 2010

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Third quarter 2009 financial results announced by Aradigm

Third quarter 2009 financial results announced by Aradigm

Positive results from Transave's Phase II ARIKACE clinical trials

Positive results from Transave's Phase II ARIKACE clinical trials

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Aradigm receives orphan drug designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe

Aradigm receives orphan drug designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe

Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis

Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Clinical trial advances cystic fibrosis therapy

Clinical trial advances cystic fibrosis therapy

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

Optical tool detects biomarkers in breath

Optical tool detects biomarkers in breath

Health effects of passive somking studied in first-of-a-kind clinical study

Health effects of passive somking studied in first-of-a-kind clinical study

Exposure to arsenic in utero and early childhood tied to lung disease and cancer in adults

Exposure to arsenic in utero and early childhood tied to lung disease and cancer in adults

Pharmaxis completes interim analysis on Bronchitol study

Pharmaxis completes interim analysis on Bronchitol study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.